YDES

News

globenewswire.comYD Bio Limited Reports Full Year 2025 Financial Resultsglobenewswire.comApr 30

globenewswire.comYD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United Statesglobenewswire.comMar 31

Trade YDES

About YD Bio Limited Ordinary Shares

Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.

CEO: Ethan Shen
IPO Date: Aug 29, 2025

Market Data

Open: $2.49
High: $2.66
Low: $2.38
Volume: 14.5K
Avg Volume: 22.9K
52W High: $25.00
52W Low: $2.38

Valuation

Market Cap: $171M
Enterprise Value: $165M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-8.0M
Revenue: $597k
Net Income: $-8.3M
Cash: $6.0M
Debt: $6.8k

Events

IPOAug 29

NASDAQ